OncoMatch/Clinical Trials/NCT04212715
Prostate SABR With Intra-Prostatic SABR Boost
Is NCT04212715 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for prostate cancer.
Stereotactic Ablative Radiation (SABR/SBRT) will be prescribed to a dose of 35 Gy in 5 fractions, once weekly to prostate with a simultaneous intra-prostatic boost to the MR detected nodule up to 50Gy. The pelvic lymph nodes and seminal vesicles will also receive 25 Gy in 5 weekly fractions.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Grade: Gleason 8-10 (Gleason)
High-risk prostate cancer, defined as at least one of: T3, Gleason 8-10, OR PSA > 20 ng/mL
Prior therapy
Cannot have received: radiation therapy
Exception: pelvic
Prior pelvic radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify